skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Review

(3644) Views  (866) Full article downloads

Authors: Eduardo Pimenta, Suzanne Oparil

Published Date May 2009 Volume 2009:5 Pages 453 - 463
DOI: http://dx.doi.org/10.2147/VHRM.S4291

Eduardo Pimenta1, Suzanne Oparil2

1Endocrine Hypertension Research Center and Clinical Center of Research Excellence in Cardiovascular Disease and Metabolic Disorders, University of Queensland School of Medicine, Princess Alexandra Hospital, Brisbane, QLD, Australia; 2Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, US

Abstract: The renin-angiotensin-aldosterone system (RAAS) is an important mediator of blood pressure (BP) and volume regulation in both normotensive and hypertensive persons and is a major contributor to hypertension-related target organ damage. The concept of renin inhibition for managing hypertension by blocking the RAAS pathway at its point of activation is very attractive since the renin-angiotensinogen reaction is the first and rate-limiting step in the generation of angiotensin II (Ang II). Aliskiren, the first in a new class of orally effective direct renin inhibitors (DRIs), is approved for the treatment of hypertension. It is effective in reducing BP in the general population of hypertensive patients and in special patient groups such as obese persons, and has a tolerability and safety profile similar to placebo. Aliskiren has renoprotective, cardioprotective and anti-atherosclerotic effects in animal models that appear to be independent of BP lowering. It reduces proteinuria in diabetic patients and has favorable neurohumoral effects in patients with symptomatic heart failure. Additional outcome trials are needed to establish the role of this novel class of antihypertensive medication in the therapeutic armamentarium.

Keywords: hypertension, renin inhibitors, renin-angiotensin-aldosterone system






 

Other articles by Professor Suzanne Oparil



Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
The relationship between adipokines, body composition, and bone density in men with chronic obstructive pulmonary disease
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
NMDA-gated ion channel research and its therapeutic potentials in neurodegenerative diseases: a review
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
COSEHC global vascular risk management quality improvement program: rationale and design
Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly
Erratum
Erratum
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University